Skip to main content

Table 2 Characteristics of patients who received first-line cytotoxic chemotherapy

From: Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience

Patient Primary site First surgery Delay 1stdiagnosis / advanced disease (months) Metastatic/Locally advanced Treatment for advanced disease before systemic treatment First-line treatment PFS/OS
(months)
1 Pleura R1 150 Metastatic Surgery (3) AI 6,9 / 22,2
2 Peritoneum R0 100 Metastatic No AI 14,5 / 70,8
3 Pleura R1 12 Metastatic No AI 5,2 / 29
4 Tip N 0 Locally advanced No PLD 1,7 / 6,4
5 Pleura R1 20 Metastatic No Adriamycine 1,4 / 22,4
6 Cerebellum Unk 128 Metastatic Surgery (1) Brostallicin 4,8 / 34,5
7 Pelvic N 0 Metastatic Radiotherapy Adriamycine 9,3 / 32,8
8 Pleura R0 20 Metastatic Surgery (1) AI 2,4 / 21,2
9 Mediastinum N 0 Locally advanced No MAID 9,1 / 12,4
10 Pleura Unk 52 Locally advanced Surgery (1) Adriamycine 60 / 68,8
11 Shoulder R1 16 Locally advanced No AI 9 / 19,4
12 Pelvic R0 0 Metastatic No Adriamycine 1,5 / 5,7
13 Pleura R2 200 Locally advanced Surgery (1) Adriamycine-Palifosfamide 6,7 – 10,7
14 Pelvic R0 156 Locally advanced No Adriamycine 17,5 / 50,8
15 Pleura R0 11 Metastatic No Adriamycine 2,1 / 2,7
16 Spine Unk 96 Locally advanced Surgery (1) AI 5,9 / 60
17 Tip N 0 Metastatic No Adriamycine 4 / 4
18 Spine R2 120 Metastatic Surgery (1) and RT AI 2,9 / 32,3
19 Pleura R1 216 Metastatic Surgery (1) and RT Adriamycine 12,5 / 27,3
20 Pleura R1 12 Locally advanced No Carboplatin-Paclitaxel 1,0 / 2,1
21 Bladder R0 32 Metastatic No Brostallicin 1,8 / 1,9
22 Pleura R0 27 Metastatic No Paclitaxel 0,4 / 0,4
23 Pleura Unk 64 Metastatic Surgery (2) Vinorelbin 5,2 / 64,5
  1. AI: Adriamycin-Ifosfamide; PLD: Pegylated Liposomal Doxorubicin; Unk: Unknown; RT: Radiotherapy; MAID: mesna, adriamycin, ifosfamide and dacarbazine; Surgery (number of surgeries).